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Critical review of nutrition, blood pressure and risk of 
hypertension through the lifecycle: do B vitamins play 
a role?
Abstract
Hypertension is the leading cause of preventable mortality worldwide, contributing to over 9 million 
deaths per annum, predominantly owing to cardiovascular disease. The association of obesity, 
physical inactivity and alcohol with elevated blood pressure (BP) is firmly established. Weight loss or 
other dietary strategies, such as the Dietary Approaches to Stop Hypertension (DASH) diet, have 
been shown to be effective in lowering BP. Additionally, specific nutrients are recognised to 
contribute to BP, with higher sodium intake linked with an increased risk of hypertension, while 
potassium is associated with a reduced risk of hypertension. Of note, emerging evidence has 
identified a novel role for one-carbon metabolism and the related B vitamins, particularly riboflavin, 
in BP. Specifically in adults genetically at risk of developing hypertension, owing to the common 
C677T polymorphism in MTHFR , supplemental riboflavin (co-factor for MTHFR) was shown in 
randomised trials to lower systolic BP by up to 13 mmHg. A BP response to intervention of this 
magnitude could have important clinical impacts, given that a reduction in systolic BP of 10 mmHg is 
estimated to decrease stroke risk by 40%. This review aims to explore the factors contributing to 
hypertension across the lifecycle and to critically evaluate the evidence supporting a role for nutrition, 
particularly folate-related B vitamins, in BP and risk of hypertension. In addition, gaps in our current 
knowledge that warrant future research in this area, will be identified.
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Hypertension is recognised as the leading preventable cause of morbidity and mortality worldwide, 
predominantly owing to cardiovascular disease (CVD), especially stroke [1,2]. Hypertension in adults and in 
pregnancy is defined as a systolic/diastolic blood pressure (BP) of 140/90 mmHg or more at rest [3,4]. The 
relationship between BP and disease risk is continuous. In middle-aged and older individuals who have a 
BP > 115/70 mmHg, it is estimated that the risk of developing CVD doubles for every 20 and 10 mmHg rise in 
systolic and diastolic BP, respectively [5]. This not only suggests that cardiovascular risk can be reduced through 
lowering of BP in hypertensive individuals, but that reduction in BP could also have substantial impacts in terms 
of CVD risk in normotensive individuals. A number of lifestyle and nutritional factors are known to influence 
BP throughout life and can contribute to the pathogenesis of hypertension. This review explores the factors 
contributing to BP variability and risk of hypertension across the lifecycle, with critical evaluation of the 
evidence for the role of nutrition, and in particular folate-related B vitamins, in preventing or delaying the onset 
of hypertension.
2 Global burden of hypertension and hypertension in pregnancy
Hypertension and its complications account for over 9 million deaths per annum [1]. The prevalence of 
hypertension worldwide rose from an estimated 600 million people in 1980 to almost 1 billion people in 2008; it 
is predicted to rise even further to 1.56 billion people by 2025 [6,7]. Given that hypertension is the second 
leading risk factor for disease burden worldwide, elevated BP is a public health concern of global proportions [2
]. Moreover, hypertension in pregnancy may lead to serious adverse complications and outcomes. Hypertensive 
disorders during pregnancy carry risks for both the pregnant woman and the foetus and have been implicated in 
the development of one-third of severe maternal morbidity in the United Kingdom [8] and one-tenth of preterm 
births [9], which are the leading cause of neonatal morbidity and mortality [10]. Thus, hypertension in 
pregnancy, as in non-pregnancy, is of major concern.
Apart from the adverse health impacts, the financial burden associated with hypertension and hypertension in 
pregnancy is enormous. In the United States, the estimated direct and indirect healthcare costs for hypertension 
were $53.2 billion in 2013, whilst the direct costs of hypertension are projected to rise to a staggering $220.9 
billion by 2035 [11]. Furthermore, the costs associated with a pregnancy complicated by pre-eclampsia, a serious 
hypertensive disorder of pregnancy, are more than double compared to the costs associated with each case of an 
uncomplicated pregnancy [12]. In 2012, the total cost burden of pre-eclampsia during the first year after delivery 
was reported at $2.18 billion in the United States [13].
Evidence from the National Health and Nutrition Examination Survey (NHANES) in the United States suggests 
that awareness of hypertension varies between different life stages with young adults (18–39 years old) being 
less aware of being hypertensive compared to middle aged (40–59 years) and older (60 years or older) 
individuals [14]. Treatment rates and BP control rates followed a similar pattern, with the older adults achieving 
the highest rate of BP control (54%). A recent study of 526,336 participants showed that whilst hypertension 
awareness and BP control rates have substantially improved over the last few decades in the developed world [
15], these trends have not been observed in the developing world where BP control rates are poor. The 
proportion of the population that is aware of their hypertensive status in developing countries is also reported to 
be low (3% in Nigeria and Namibia) [16]. Furthermore, the majority of women suffering from hypertension and 
hypertensive disorders during pregnancy in developing countries were reported to be unaware of their condition 
[17–19]. Lack of awareness compromises treatment and BP control rates, which in turn can lead to an increase 
in the occurrence of complications associated with hypertension, such as end-organ damage and pathological 
vascular and neurological changes [3]. Thus, awareness campaigns on hypertension might benefit BP control 
rates by increasing the proportion of people adhering to their antihypertensive medication.
3 Regulation, measurement and treatment of blood pressure
Homeostasis, and hence BP control is primarily regulated by the renin-angiotensin-aldosterone system (RAAS), 
the baroreceptor reflex and the presence of vasoactive factors in the circulatory system [20,21]. The complex 
RAAS is involved in the long-term regulation of BP and essentially modulates systemic vascular resistance and 
the reabsorption of sodium and water which ultimately leads to a BP increase. The proteolytic renin enzyme, 
which is released in the blood stream by the granular cells of the juxtaglomerular apparatus in the kidney, cleaves 
angiotensinogen to angiotensin I. The angiotensin-converting enzyme (ACE) then facilitates the conversion of 
the inactive peptide angiotensin I to the active peptide angiotensin II. Angiotensin II acts directly on angiotensin 
type I and II receptors in the vascular system to cause vasoconstriction and thereby a BP rise. In addition, 
angiotensin II also stimulates the release of the steroid hormone aldosterone from the adrenal cortex to further 
promote sodium and water reabsorption. As a result, blood volume increases further and, therefore, BP increases 
[20,21]. Moreover, the short-term regulation of BP is mediated by the baroreceptor reflex. In response to vessel 
wall distention, baroreceptors, which are located on the aortic arch and carotid sinus, increase the afferent 
impulse activity [20,22]. This causes a decrease in the activity of the efferent sympathetic nervous system and an 
increase in the activity of the parasympathetic nervous system to augment vagal tone, stimulate bradycardia and 
vasodilation and eventually lower BP. As well as RAAS and the baroreceptor reflex, endothelial mechanisms are 
implicated in BP regulation [20]. The vascular endothelium, which constitutes the inner cellular lining of blood 
vessels, synthesises vasoactive factors such as nitric oxide and endothelin-1. Nitric oxide mediates vasodilation 
and hence, BP lowering, whilst endothelin-1 causes vasoconstriction and in turn an increase in BP. Given that 
BP is the product of cardiac output, systemic vascular resistance and arterial elasticity, an imbalance of sodium 
reabsorption, impaired neurogenic control, endothelial dysfunction and/or increased arterial stiffness can increase 
the risk of developing hypertension [20,21].
BP refers to the force exerted by blood on the walls of the large arteries in the systemic circulation. Specifically, 
systolic BP refers to the maximum pressure in the arteries during a contraction of the heart muscle (systole), and 
diastolic BP refers to the lowest pressure measured within the arteries when the heart muscle relaxes between 
beats (diastole) [22]. In a clinical setting, BP is predominantly measured using the auscultatory method to detect 
the appearance and disappearance of Korotkoff sounds in the brachial artery, which represent systolic and 
diastolic BP, respectively [23]. An alternative non-invasive BP monitoring method is the oscillometric technique, 
wherein BP is measured using an automated cuff that yields estimates of systolic and diastolic BP by the 
observation of oscillations in the cuff pressure [23]. Given that patients may present to the clinic with white coat 
hypertension (hypertensive BP levels in the clinic but not outside the clinic) or masked hypertension 
(hypertensive BP levels outside the clinic but not at the clinic) and that BP varies throughout the day and night, 
an out of office BP measurement over an extended period of time should be considered for the diagnosis of 
hypertension [3,23]. Ambulatory BP monitoring (ABPM) is the reference standard as it records BP over a 24-h 
period and can, therefore, track circadian rhythm and prevent false diagnosis. In the case that an ABPM is not 
suitable or tolerated by the patient, a home BP monitoring would be recommended to confirm the diagnosis of 
hypertension [3].
The main goal of antihypertensive therapy is to treat and control hypertension, and in turn, to prevent the 
associated complications, particularly myocardial infarction and stroke. The National Institute of Health and Care 
Excellence (NICE) advises that in adults under 80 years, BP should be reduced to <140/90 mmHg, whereas for 
older adults over 80 years, BP should be reduced to <150/90  mmHg [3]. In women who are pregnant or 
planning to become pregnant, the target BP is 135/80  mmHg [4]. In infants and children, the targets are 
BP  <  99 th and 95 th percentile for age, sex and height, respectively [24,25]. In hypertensive children and 
adolescents who have specific conditions (e.g. chronic renal disease, diabetes or hypertensive end-organ 
damage), it is recommended that BP be reduced to less than the 90
th
 percentile for age, sex and height [25]. 
Pharmacologic treatment of hypertension involves the use of antihypertensive agents, such as ACE inhibitors, 
angiotensin II receptor blockers, α-adrenergic receptor blockers, β-blockers, calcium-channel blockers (CCBs) 
and diuretics; polytherapy is recommended whereby two or more antihypertensive medications are used in 
combination [3]. However, in pregnancy and breastfeeding, certain antihypertensive agents, such as ACE 
inhibitors, are contraindicated as they could be harmful to mother, foetus and offspring [4,26]. During the 
perinatal and antenatal periods, labetalol (β-blocker), nifedipine (CCB) and methyldopa (centrally acting 
antiadrenergic) are recommended as suitable options for the treatment of hypertension [4]. Furthermore, in 
women who have chronic hypertension or are at high risk for pre-eclampsia, aspirin is recommended from 12 
weeks of pregnancy until birth [4]. In infancy, the only antihypertensive agent proven to effectively reduce BP is 
captopril (ACE inhibitor) [27]. Apart from antihypertensive medications, statin therapy for the treatment of 
hyperlipidaemic hypertensive patients has been shown to result in a BP reduction and improved BP control rates, 
irrespective of antihypertensive medication [28]. Furthermore, the BP-lowering effect of statins seems to be 
independent of statin type or dosage administered [29]. Moreover, weight loss resulting from pharmacological 
(orlistat, rimonabant and topiramate) and surgical (bariatric surgery) interventions has also been shown to lead to 
a decrease in BP and improved BP control rates [30–34].
3.1 Factors contributing to hypertension
It is widely recognised that hypertension is a multifactorial condition involving the interaction of modifiable and 
non-modifiable risk factors.
3.2 Modifiable risk factors for hypertension
The link between obesity and hypertension is well documented. An estimated 15, 25 and 40% of normal weight, 
overweight and obese individuals, respectively, are reported to have hypertension [35]. Excess body mass not 
only affects BP in the general adult population but can also have an adverse effect on BP in pregnancy and 
childhood. One systematic review showed that women who had a pre-pregnancy body mass index (BMI) of 
≥30  kg/m2 were up to 10 times more likely to develop gestational hypertension and pre-eclampsia [36]. 
Furthermore, evidence from a prospective birth cohort study in childhood showed that children who were 
overweight at 5 and/or 14 years of age had a higher systolic and diastolic BP at age 14 years compared to those 
who had a normal BMI at 5 and 14 years [37]. Therefore, controlling the global obesity epidemic for the 
prevention and treatment of hypertension at all life stages is of paramount importance.
It is well established that lack of regular physical activity adversely influences BP, irrespective of whether the 
individual is normotensive or hypertensive. One meta-analysis of 65 studies investigating the acute effects of 
exercise on BP showed that in the hours following an exercise session, systolic and diastolic BP were reduced 
by 4.8 and 3.2 mmHg [38], respectively. Another systematic review of 27 randomised controlled trials (RCTs) in 
individuals with hypertension reported that regular medium-to-high intensity aerobic activity was associated with 
lower systolic BP by 11 mmHg and diastolic BP by 5 mmHg [39].
Although the evidence in relation to the effect of smoking on BP is conflicting [40], most studies report smoking 
as an important determinant of hypertension [41,42]. Not only is active smoking associated with an increased 
risk of incident hypertension [41], but passive smoking can also have detrimental effects on BP. Of note, Cabral 
et al. [42] recently reported a higher BP at 4 years of age in children whose mothers smoked prior to conception 
through pregnancy and childhood compared with those children of non-smoker mothers. This reinforces the 
importance and need of effective smoking cessation programmes and smoke-free environments from early life 
through older age in order to maintain more optimal BP, and thus better cardiovascular health.
Alcohol and caffeine consumption have also been associated with BP. A recent meta-analysis of 36 alcohol 
intervention trials with a total of 2,865 participants estimated that a reduction in alcohol consumption for at least 
7 days in normotensive or hypertensive individuals who drank more than 2 drinks per day was associated with a 
lowering of systolic and diastolic BP by 5.5 and 4.0 mmHg, respectively [43]. Caffeine intake has also been 
associated with BP, but the evidence is somewhat unclear. Caffeine intakes of 200–300 mg have been shown to 
lead to an acute increase in systolic BP of 8.1 mmHg and diastolic BP of 5.7  mmHg [44], whilst the BP 
response to caffeine seems to be exacerbated in hypertensive patients [45]. Although the evidence on the effect 
of habitual consumption of caffeine on BP and hypertension risk is inconsistent [46,47], most studies indicate 
that regular caffeine intake does not increase BP or hypertension risk [44]. This may relate to the development of 
partial haemodynamic tolerance, whereby the antagonising effect of caffeine is dampened by an eventual 
upregulation of adenosine receptors [44,48].
There is considerable evidence that certain dietary patterns and specific nutrients can strongly influence BP and 
potentially prevent or treat hypertension. Such evidence will be discussed in section  of this review.
3.3 Non-modifiable risk factors for hypertension
Advancing age results in structural modifications in the arteries and in particular large arterial stiffness, which in 
turn leads to BP changes over time [49]. Findings from the longitudinal Framingham Heart Study demonstrated 
that systolic BP increases linearly between the ages of 30 and 84 years, whilst diastolic BP increases until 50–60 
years and then slowly declines [50]. Consequently, isolated systolic hypertension predominantly affects older 
adults [51]. The third NHANES in the United States showed that 3 of every 4 hypertensive adults is aged ≥50 
years, reiterating that advancing age is a key determinant of hypertension [52].
Sex differences in BP and risk of hypertension are also observed. The prevalence of hypertension is higher in 
males up to 65 years, whereas after 65 years the risk of hypertension appears to be higher in females [11,53]. It 
has been suggested that these sex differences in the epidemiology of hypertension might be due to a potential 
protective effect against hypertension development of sex hormones in women of reproductive age, which is 
reversed after menopause [54]. However, research investigating the effect of hormone replacement therapy on 
BP in postmenopausal women is controversial, indicating that the sex-related differences on BP may be more 
complex than initially perceived [55–57].
Racial and ethnic differences have also been shown in epidemiological studies to affect the incidence and 
prevalence of hypertension. A study conducted in American adults, aged 20 years or older, showed that the age-
adjusted prevalence of hypertension in Asians, Hispanics, Whites and Blacks was 27.0, 29.0, 29.2 and 42.4%, 
respectively [53]. The same study also showed that, compared to Hispanic adults, the life expectancy of Black 
Americans was shorter by 7 years, possibly owing to higher rates of hypertension. Given that the difference in 
BP observed between Blacks and Whites was shown to begin at 15 years of age and that BP tracks with age, 
interventions to prevent hypertension in this at-risk population should ideally be commenced in adolescence [58].
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There is strong evidence suggesting that an estimated 48–60% of systolic and 34–67% of diastolic BP variance 
may be attributed to heritability [59,60]. The prevalence of hypertension was shown to be significantly higher in 
individuals who have family history of hypertension compared to those without [61]. In addition, BP levels 
amongst normotensive individuals were also found to be higher in those with a positive family history [62]. 
Furthermore, Ness et al. [63] demonstrated that the risk of developing hypertension in pregnancy and pre-
eclampsia in women who had at least two first-degree family members with hypertension was twofold higher 
than those who had no family history. Thus, BP should be closely monitored in individuals with a family history 
of hypertension, even when BP is normal.
4 Blood pressure and risk of hypertension through the lifecycle
4.1 Pregnancy
Multiple physiological changes occur during pregnancy, leading to an initial decrease in BP until the 20
th
 
gestational week, followed by a progressive increase until term [64–66]. Hypertension is not only a risk factor in 
the general population but is of particular concern in pregnant women, with up to 15% of pregnancies 
complicated by hypertension [67]. In such pregnancies, the BP pattern deviates from the typical one. A recent 
meta-analysis by de Haas et al. [68] showed that the mid-gestational systolic BP drop is absent in hypertensive 
pregnancies, while diastolic BP initially decreases and after mid-pregnancy both systolic and diastolic BP rise to 
higher levels and in a steeper slope than in normotensive pregnancies.
Hypertension in pregnancy can be defined as i) chronic hypertension, ii) gestational hypertension or iii) pre-
eclampsia [4]. Chronic hypertension refers to pre-existing hypertension or hypertension diagnosed before the 
20
th
 week of gestation, whereas gestational hypertension is defined as high BP occurring for the first time after 
the 20
th
 week of gestation. Gestational hypertension usually resolves postpartum, however, if high BP persists 
beyond the 12
th
 week after pregnancy, then the diagnosis of chronic hypertension can be assigned [69]. Pre-
eclampsia is a condition unique to human pregnancy and is characterised by the presence of hypertension and 
proteinuria or hypertension and end-organ dysfunction with or without proteinuria [4]. The occurrence of 
seizures in combination with the pre-eclamptic phenotype leads to the diagnosis of eclampsia.
The prevalence of hypertension and pre-eclampsia has increased in the recent years, possibly due at least in part 
to advanced maternal age and the obesity epidemic [70,71]. Chronic hypertension, gestational hypertension and 
pre-eclampsia or eclampsia complicate 1–5%, 6–7% and up to 5–7% of all pregnancies, respectively [72]. 
Compared to women who had normotensive pregnancies, women with a history of hypertension in pregnancy 
are at an increased risk for hypertension and stroke in later life [69]. Furthermore, women with a history of 
hypertensive disorder of pregnancy are typically diagnosed with hypertension on average 8 years earlier than 
those with no such history [73]. This suggests that hypertension in pregnancy not only influences pregnancy 
outcomes, but also increases the risk of hypertension and age of onset of hypertension in later life.
4.2 Infancy
Defining normal BP in infants, especially neonates, is extremely complex as BP and the pattern of BP at this 
stage of life are strongly correlated with birth weight, size, gestational age, chronological age and postmenstrual 
age (i.e. gestational age plus chronological age) [74–76]. BP of term newborns remains unchanged in the first 
15 minutesfifteen minutes after birth, whereas BP of newborns who were born preterm decreases steadily within 
the first 3 hoursthree hours of life [77,78]. Eventually, BP spontaneously rises during the first 5–7 days in 
neonates, after which point the rise in BP is less rapid [75,79,80]. It has also been reported that the rate of 
increase in systolic BP during infancy is greater than the rate of increase in diastolic BP [81]. Moreover, the BP 
rise in preterm newborns is reported to be more pronounced than in term newborns [79,82]. However, after 14 
days of life, BP in preterm neonates appears to stabilise and is found to be similar to that of term infants [82].
Hypertension in infants aged 1 month to 1 year is defined as a BP ≥ 95 th percentile for age, sex, height and 
weight [74], whereas hypertension in neonates is defined as a systolic BP greater or equal to the 95
th
 percentile 
for chronological age, postmenstrual age, sex, birth weight and appropriateness of size for age [24,74]. Although 
5% of infants are hypertensive by definition, the reported incidence of infantile hypertension ranges from 0.2% 
in healthy newborns, to 3.0% in the neonatal intensive care unit [74,83].
4.3 Childhood and adolescence
In children, BP increases progressively and is similar between the two sexes before puberty. The upward trend in 
BP continues during adolescence, albeit the incline is steeper. In particular, males experience a more marked 
pubertal rise than females and the widely accepted sex-related differences in BP are slowly established [84]. The 
prevalence of hypertension and pre-hypertension in British children and adolescents was estimated at 2.3 and 
6.9%, respectively, in 2007 [84].
In the United Kingdom, hypertension in children and adolescents is defined as a BP above the 98
th
 percentile for 
age [84]. Hypertension in childhood and adolescence is becoming a major concern as a strong association has 
been established of paediatric hypertension and pre-hypertension with hypertension and CVD risk in adulthood [
85,86]. An estimated 1 in every 2 hypertensive adults had elevated BP in childhood [87]. As in adulthood, 
paediatric hypertension may also result in irreversible end-organ and vascular damage [88,89]. The collated 
evidence suggests that BP monitoring in children and adolescents is important, but in practice, BP is likely to be 
overlooked in most paediatric settings. Despite having their BP measured and recorded, three quarters of all 
hypertensive and pre-hypertensive paediatric patients remain undiagnosed [90].
4.4 Adulthood
Systolic and diastolic BP continuously increase from early adulthood to middle-age with a systolic/diastolic BP 
of <120/80 mmHg considered as normal BP, since it is associated with the lowest CVD risk and related adverse 
outcomes [51]. The prevalence of hypertension in adults aged 18–39 years and 40–59 years is reported to be 7.3 
and 32.7%, respectively [14]. Of note, normotensive individuals at age 55 are reported to have a 90% lifetime 
risk of developing hypertension [91]. In addition, individuals who experience a reduction or no change in BP by 
the age of 55 have the lowest lifetime risk for CVD (22–41%), compared to those who had or developed 
hypertension by that age (42–69%) [92]. Thus, primary prevention of hypertension is crucial to alleviate a 
potential public health burden. It is extensively documented that the use and duration of use of hormonal 
contraceptives (the most widely used method of birth control by women) are associated with increased BP and 
risk of hypertension [93]. However, cessation of hormonal contraceptives eventually cancels the excess 
hypertension risk and restores BP to baseline levels [94]. Hence, the BP of women who are taking hormonal 
contraceptives should be regularly monitored and if needed, an alternative method of birth control considered.
In adults aged 18–39 years, BP within the normal range is associated with a reduced risk of heart failure 
compared with a systolic or diastolic BP of 130  mmHg or 80  mmHg or more, respectively [95]. These 
cardiovascular outcomes are thought to be a result of pathological changes in the heart and the vasculature, 
which are caused by elevated BP. Recently, three-dimensional echocardiography revealed that, even after 
adjusting for relevant confounders, higher cumulative BP from early adulthood to middle age is linked to left 
atrial remodelling and dysfunction [96]. Additionally, findings from the ‘Insight 46’ epidemiological study of 
dementia-free individuals showed that high BP in midlife is associated with increased white matter 
hyperintensity volume and smaller whole-brain volume at 70 years of age, suggesting that BP within this age 
group is a predictor for potential adverse outcomes in later life [97].
4.5 Older age
Systolic BP is known to increase with age throughout life whereas diastolic BP increases until about 60 years 
and then declines [98]. Evidence from the United States showed that two thirds of adults (60 years or older) 
were hypertensive [14]. Interestingly, recent results from a population-based cohort study of older participants 
over a 20-year period revealed that both systolic and diastolic BP decline during the 18 to 14 years before death; 
64% of these individuals experienced a reduction in systolic BP of greater than 10 mmHg [99]. In line with the 
findings of Ravindrarajah et al. [100], the decline in BP was shown to be accelerated in the last two years of life 
[99].
BP reduction and control in older age remain important for the prevention of CVD [5,101]. Evidence shows that 
standard BP control (systolic BP of <140  mmHg) in older hypertensive patients led to a reduction of 
cardiovascular events as expected [102]. Of note, the Systolic BP Intervention Trial (SPRINT) showed that 
compared to standard BP treatment, intensive BP treatment (BP target of <120 mmHg) in older adults with 
hypertension resulted in lower death rates from CVD (by 43%) and any cause (by 27%) [103]. In contrast to the 
beneficial effects of intensive treatment reported in the SPRINT trial, another study found that older, treated 
hypertensives with a systolic BP of <135 mmHg and 125 mmHg were at increased risk of mortality and incident 
heart failure, respectively [104]. Thus, the issue of BP management in older adults is somewhat controversial. 
Also, use of antihypertensives and low BP in older adults have been linked with increased risk for serious fall 
injuries in some studies [105,106], whilst other studies show no such associations [107]. Apart from the 
importance of effective BP management for cardiovascular health and mortality, BP plays a key role in cognitive 
function and brain health. A systolic BP of ≥130 mmHg in treated hypertensive patients aged 75 years or older 
was associated with less cognitive decline after 1 year [108]. Collectively, the evidence suggests that BP in older 
age should be regularly monitored and tightly regulated in order to maintain health and wellness.
5 Nutrition interventions to lower blood pressure
5.1 Energy intake and obesity
Body weight, weight gain and obesity are strongly associated with BP [35,109]. Thus, lifestyle modifications to 
induce weight reduction is the first line of treatment in pre-hypertensive and hypertensive patients [3,4,25], with 
reports estimating that for every 10 kg of weight loss, systolic BP potentially decreases by an estimated 5–
20 mmHg [51]. However, weight loss of this magnitude is extremely difficult to achieve in practice for both 
health professionals and patients, and even harder to sustain in the longer term. Of note, the Look AHEAD 
(Action for Health in Diabetes) study, a multicentred RCT of 5,145 overweight or obese individuals with type 2 
diabetes, tested the effectiveness of two approaches to weight loss over one year [110]. One approach was an 
intensive lifestyle intervention involving a programme of behavioural modifications for weight management, a 
diet plan with caloric restriction and increased physical activity. The other approach was ‘usual care’, comprising 
of a programme of diabetes support and education. After one year of follow-up, the percentage of initial body 
weight loss was greater in those assigned to the intensive lifestyle intervention (8.6%) compared with those 
assigned to receive usual care (0.7%). Furthermore, the weight loss achieved by the intensive lifestyle 
intervention group led to greater reductions in systolic/diastolic BP (−-6.8/-3.0 mmHg) compared to the usual 
care group (−-2.8/-1.8 mmHg) and prevented the increase in antihypertensive medication users at one year 
(−-0.1% vs 2.2%).
5.2 Dietary patterns
Emerging evidence has identified certain dietary patterns to be linked with BP across all age groups, most 
notably, the Dietary Approaches to Stop Hypertension (DASH) diet, which is characterised by a high 
consumption of fruits, vegetables, whole grains and low-fat dairy and a reduced consumption of saturated and 
total fat (Table 1). In comparison to a control typical ‘American’ diet, comprised of low fruit, vegetable and dairy 
product consumption and high consumption of saturated and total fat, the DASH diet was shown to be highly 
effective in reducing systolic/diastolic BP among normotensive (by 3.5/2.1 mmHg) and hypertensive individuals 
(by 11.4/5.5 mmHg) after 8 weeks of intervention [111]. Of interest, the effect of the DASH diet on BP was 
found to be maintained at 8 months after completion of the trial [112]. Moreover, the DASH diet is not only 
effective in non-pregnant adults, but it has also been shown to have a BP-lowering effect in pregnant women 
and adolescents [113–115]. The effects of the DASH diet on BP may be at least partly explained by dairy-rich 
nutrients including calcium, as the recently published INTERnational study on MAcro/micronutrients and blood 
Pressure (INTERMAP) confirmed that low-fat dairy consumption was associated with lower BP in 2,694 
participants aged 40–59 years [116]. Unsurprisingly, modifications to the DASH diet to reduce sodium intake or 
body weight have been shown to further lower BP compared to the DASH diet alone [112,117,118]. Taken 
together, this evidence supports the implementation of the DASH diet or its modified versions as an effective 
lifestyle intervention for the prevention, and potentially the treatment, of hypertension through the lifecycle.
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Table 1
Effectiveness of selected nutritional interventions to lower systolic blood pressure.











with the ‘DASH’ diet vs 
a diet rich in fruits and 
vegetables only vs a 
control diet
DASH diet : rich in 
fruits, vegetables, whole 
grains and low-fat dairy 
and low saturated and 
total fat
Control ‘American’ diet : 
low in fruits, vegetables 
and dairy products and 
Compared with the control diet, the DASH diet 
lowered systolic BP by 5.5 mmHg overall, by 
3.5 mmHg in normotensives and by 
11.4 mmHg in hypertensives. The BP-lowering 
effect of the DASH diet was greater than that of 
the diet rich in fruits and vegetables only
i The table layout displayed in this section is not how it will appear in the final version. The representation below is 
solely purposed for providing corrections to the table. To preview the actual presentation of the table, please view 
the Proof.









and at high CVD 
risk
A 3-month intervention 
with a ‘Mediterranean’ 
diet with virgin olive oil 
(1 L/week) vs a 
Mediterranean diet with 
nuts (30 g/day) vs a low-
fat diet
Mediterranean diet : 
high in olive oil, nuts, 
fruits and vegetables, 
and low in red meat and 
processed foods
Compared with the low-fat control diet, 
systolic BP decreased in response to the 
Mediterranean diet with olive oil by 5.9 mmHg 
and the Mediterranean diet with nuts by 
7.1 mmHg
Specific nutrients











Potassium chloride supplementation lowered 
systolic BP by 5.0 mmHg








A 2-week reduced-salt 
diet followed by the 















3-month RCT during 
winter time with 1000, 
2000 or 4000 IU/day 
cholecalciferol vs 
placebo
A dose-response relationship of cholecalciferol 
supplementation and systolic BP was shown, 





























2-year RCT with high 
dose combined FA 
(2.5 mg), pyridoxine 
(25 mg) and cobalamin 
(0.4 mg) vs negligible 
dose











2-year RCT with 
combined L-5-
methylTHF (1 mg), 
vitamin B12 (500 μg) 
B vitamin intervention did not affect BP
Apart from the DASH diet, other dietary patterns or foods have been linked with improved BP and 
cardiovascular health. The ‘Mediterranean’ diet, which includes high intakes of extra virgin olive oil, nuts, fruits, 
vegetables, and minimal intakes of red meat and processed foods [119], has been the subject of a number of 
studies. The Prevención con Dieta Mediterránea (PREDIMED) randomised trial reported on the effects of this 
dietary pattern in older adults at high cardiovascular risk [120]. Compared to a low-fat control diet, the 
Mediterranean diet with extra virgin olive oil or with nuts resulted in significant reductions in systolic BP of 5.9 
and 7.1 mmHg, respectively, at 3 months [120]. Although the mechanism explaining the BP-lowering effect of 
the Mediterranean diet is unclear, it may be mediated by the typically high polyphenol content of this dietary 
pattern. Dietary polyphenols are associated with an increase in the endothelial production of nitric oxide which, 
in turn, stimulates vasodilation and hence mediates a reduction in BP [121]. Although there is evidence of the 
beneficial effects of the Mediterranean diet on BP, data on the prevention and treatment of hypertension with this 
dietary pattern are not conclusive [122]. Accumulating evidence also indicates that increased fruit and vegetable 
consumption is inversely associated with hypertension and CVD [123]. Of interest, a crossover RCT 
investigating the acute BP effect of beetroot juice (with four doses of either 0, 100, 250 and 500 g) showed that 
BP was significantly reduced over the 24-h post-ingestion period, in a near dose-response manner [124]. The 
mechanism by which beetroot juice reduces BP may be mediated through the nitric oxide pathway [125]. 
Nitrates, which are abundantly found in beetroot juice, are reduced to nitrites by the microbiome in the oral 
cavity. Endothelial nitric oxide synthase (eNOS) further reduces nitrites to nitric oxide and stimulates relaxation 
of the vascular smooth muscle, thus leading to a reduction in BP [125].
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No difference in systolic BP response between 
FA combined with enalapril (−27.1 mmHg) and 
enalapril alone (−27.1 mmHg). However, FA 
reduced the risk of first stroke by 21%
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Riboflavin lowered systolic BP by 13.4 mmHg, 
specifically in those with the MTHFR  677 TT 
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16-week RCT with 
riboflavin (1.6 mg/day) 
vs placebo
Riboflavin lowered systolic BP by 5.6 mmHg. 
BP control rates increased from 32% to 57% in 
response to riboflavin supplementation
Abbreviations: DASH, Dietary Approaches to Stop Hypertension; BP, blood pressure; CVD, cardiovascular disease; RCT, 
randomised controlled trial; FA, folic acid; THF, tetrahydrofolate; MTHFR , methylenetetrahydrofolate reductase.
5.3 Specific nutrients
A meta-analysis of 34 randomised trials (3,230 participants) showed that a reduction of 4.4 g in daily salt intake 
for at least four weeks resulted to a decline of 4.2 mmHg in systolic BP and 2.1 mmHg in diastolic BP [126]. 
Given that the current average dietary salt intake is estimated to be 9–12 g/day [127], a reduction of at least 4.4 g 
in daily salt intake to comply to the World Health Organisation's target of less than 5 g/day [128], could have 
major beneficial impact on cardiovascular and public health. In fact, a modest decrease of 2 mmHg in diastolic 
BP at a population level (potentially achievable via a reduced salt intake) could be predicted to result in 17, 6 and 
15% reduction in hypertension prevalence, coronary heart disease risk and stroke risk, respectively [129]. A 
recently published meta-analysis of 133 randomised trials including 12,197 participants showed a dose-response 
relationship of sodium reduction with BP, whereby each 50 mmol reduction in 24-h sodium excretion (i.e. the 
best measure of salt intake) was associated with a decrease in systolic and diastolic BP of 1.10 and 0.33 mmHg, 
respectively [130]. However, evidence suggests that the effect of sodium intake on BP varies greatly between 
individuals since the BP of some individuals rises after sodium loading, whilst the BP remains unaffected in 
others [131,132]. In those who do experience a BP change with reduced sodium intake or sodium loading, the 
diagnosis of ‘sodium sensitivity’ can be assigned [131]. Furthermore, sodium sensitivity has been shown to exist 
in normotensives as well as those with hypertension, albeit with a higher prevalence among the latter [131,132]. 
However, currently there is no agreement on the characterisation of the sodium sensitive individuals [133,134].
BP responses to potassium have been examined in numerous observational and interventional studies. A meta-
analysis of 22 RCTs and 11 cohort studies in adults by Aburto et al. [135] showed an inverse association of 
potassium intake with BP and stroke, though a dose-response relationship was absent. Additionally, the most 
marked systolic BP reduction (7.2 mmHg) was exhibited when potassium intake was 90–120 mmol/day [135]. 
Furthermore, observational studies in pregnancy found serum potassium to be significantly lower in hypertensive 
pregnancies than in normotensive pregnancies [136].
Calcium supplementation (1  g/day) has been shown to reduce BP in most, but not all studies [137–139]. 
Moreover, calcium supplementation during pregnancy resulted in lower maternal BP, lower risk of pre-eclampsia 
and lower offspring BP in the early years of life [140–142]. These findings suggest that, apart from a potential 
role in the treatment of hypertension, calcium may have a role in maintaining healthy BP from in utero to older 
age.
Magnesium is another nutritional factor that may influence BP. A meta-analysis of 34 randomised trials involving 
2,028 individuals demonstrated very small, but significant, BP reductions with magnesium supplementation [143
]. Interestingly, co-administration of magnesium with antihypertensive medication has been shown to have an 
additive effect on BP reductions compared to antihypertensive medication alone. Hence, magnesium therapy for 
hypertension could lead to improved BP control in hypertensive patients [144].
A protective role of polyphenols in CVD and hypertension has been suggested [145,146]. An RCT using a diet 
with either polyphenol-rich olive oil (~30  mg/day) or polyphenol-free olive oil in young women with pre-
hypertension and mild hypertension demonstrated a notable decrease in systolic and diastolic BP of 7.9 and 
6.7 mmHg, respectively, in response to the polyphenol intervention [147]. Furthermore, recent findings have 
shown that the effect of polyphenols on BP might be sex specific and confined to certain polyphenol classes and 
subclasses [148,149].
The role of vitamin D in bone health and calcium metabolism is well established, whereas its effect on BP and 
hypertension remains unclear. A 3-month RCT with placebo or 1000, 2000 or 4000  international units of 
vitamin D3 per day showed that vitamin D3 supplementation had no effect on diastolic BP, whilst systolic BP 
was significantly reduced in a dose-response manner [150]. In contrast, a recent systematic review and meta-
analysis of randomised trials (1,687 participants) showed that BP remained unchanged in response to vitamin D3 
supplementation in vitamin D deficient adults [151]. Therefore, the role of vitamin D supplementation in BP is 
unclear.
6 One-carbon metabolism, related B vitamins and blood pressure
6.1 Role of B vitamins within one-carbon metabolism
Tetrahydrofolate (THF)-mediated one-carbon metabolism encompasses a complex network of interdependent 
pathways that support a variety of processes, including purine and thymidine biosynthesis, amino acid 
homeostasis and epigenetic mechanisms (Fig. 1). Biologically active folates are present as reduced co-factor 
forms, i.e. THF, with the predominant form in plasma and cells carrying a methyl group, i.e. 5-methylTHF (5-
MTHF). Folic acid, the synthetic form of folate, has to be sequentially reduced to form dihydrofolate and then 
THF via dihydrofolate reductase. THF then enters the folate cycle and the pyridoxal 5′-phosphate (PLP; active 
form of vitamin B6)-dependent conversion of serine to glycine donates a methyl group to THF to form 5, 10-
methyleneTHF, which is then converted to 5-MTHF [152]. Riboflavin (vitamin B2) is also involved in one-
carbon metabolism in one of two co-factor forms, flavin mononucleotide (FMN) and flavin adenine dinucleotide 
(FAD) [153]. FMN is required by pyridoxine-phosphate oxidase to biologically convert most naturally available 
vitamin B6 to the active co-factor form PLP in tissues, whereas FAD is required as a co-factor for the key folate-
metabolising enzyme, methylenetetrahydrofolate reductase (MTHFR) [152,153]. The flavoprotein MTHFR 
catalyses the conversion of 5,10-methyleneTHF to 5-MTHF which then serves as a methyl donor for the 
regeneration of methionine from homocysteine [152]. The reaction responsible for homocysteine remethylation 
and consequent THF regeneration links the folate cycle with the methionine cycle and is catalysed by the 
methylcobalamin (vitamin B12)-dependent methionine synthase. Remethylation of homocysteine to methionine 
is of particular importance as methionine and adenosine triphosphate act as the substrates for S-
adenosylmethionine synthetase to form S-adenosylmethionine; the universal methyl donor which plays a key 
role in epigenetics, biosynthetic processes and in sulphur metabolism [152].
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6.2 One-carbon metabolism in relation to adverse pregnancy outcomes and cardiovascular 
disease
One-carbon metabolism requires an adequate supply of folate, along with vitamin B12, vitamin B6 and 
riboflavin. Sub-optimal status of any of these B vitamins and/or genetic polymorphisms on B vitamin-dependent 
enzymes in one-carbon metabolism, can result in a disruption of one-carbon metabolic pathways which can lead 
to adverse phenotypes, even if dietary folate and related B vitamin intakes are adequate [154,155].
(Colour online and in press) B vitamins and one-carbon metabolism. B2, vitamin B2 (riboflavin); B6, vitamin B6; B12, 
vitamin B12; BHMT, betaine-homocysteine methyltransferase; CBS, cystathionine β-synthase; CTH, cystathionine γ-lyase; 
DHFR, dihydrofolate reductase; dTMP, deoxythymidine monophosphate; dUMP, deoxyuridine monophosphate; FAD, flavin 
adenine dinucleotide; FMN, flavin mononucleotide; GNMT, glycine N-methyltransferase; MAT, methionine 
adenosyltransferase; MeCbl, methylcobalamin; MS, methionine synthase; MT, methyltransferases; MTHFR, 
methylenetetrahydrofolate reductase; MTHFD, methylenetetrahydrofolate dehydrogenase; PLP, pyridoxal 5′-phosphate; PPO, 
pyridoxine-phosphate oxidase; SAHH, S-adenosylhomocysteine hydrolase; SHMT, serine hydroxymethyltransferase; TS, 
thymidylate synthase. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web 
version of this article.)
Folate is of particular importance in pregnancy and foetal development owing to its essential role in cell division 
and tissue growth. The role of periconceptional maternal folate in the prevention of neural tube defects is widely 
recognised, however, folate has a number of other roles throughout pregnancy with important impacts for 
maternal and offspring health [156]. Supplementation with folic acid has been shown to prevent the decline in 
maternal folate concentrations that typically occurs during pregnancy [157] and hence, prevent the occurrence of 
megaloblastic anaemia of pregnancy [158]. Given that the regeneration of methionine from homocysteine is 
dependent on folate, a low folate status leads to elevated homocysteine concentrations, a phenotype that can be 
alleviated in response to intervention with folic acid alone or in combination with related B vitamins [159].
There is extensive evidence to link low folate status (and/or elevated homocysteine concentrations) with an 
increased risk of adverse pregnancy complications and outcomes including gestational hypertension [160], 
preeclampsia [161–163], placental abruption [164], pregnancy loss [165,166], low birth weight and intrauterine 
growth restriction [167]. The risk of gestational hypertension and pre-eclampsia was shown in some studies to be 
reduced by folic acid supplementation during pregnancy [160], albeit the evidence is somewhat conflicting [168
]. Of note, recent evidence from an RCT with high dose folic acid beyond the first trimester of pregnancy 
showed that folic acid had no beneficial effect on pre-eclampsia in women at high risk for this condition [168]. 
Such inconsistencies might be explained by intra- and inter-population genetic variation and/or differences in 
nutritional status of folate and related B vitamins. Of interest, genome-wide association studies (GWAS) and 
epidemiological studies have linked the common MTHFR  C677T polymorphism with hypertension and 
hypertension in pregnancy [155,169–171]. The role of this polymorphism in BP will be discussed further in 
section 7.3.
Considerable evidence links one-carbon metabolism with CVD, especially stroke [172]. Most notably, findings 
from the 5-year China Stroke Primary Prevention Trial (CSPPT) of 20,702 hypertensive patients showed that 
intervention with folic acid resulted in no BP-lowering effect, but significantly reduced the incidence of first 
stroke by 21% (Table 1) [173]. Of note, the MTHFR  C677T polymorphism has been linked with several 
adverse health outcomes, including an increased CVD risk by up to 40% [172]. Less well recognised is evidence 
showing that the MTHFR  C677T polymorphism is associated with an increased risk of hypertension and 
hypertension in pregnancy by up to 87% [169,174–177].
Most relevant studies examining adverse pregnancy and CVD outcomes in relation to folate have focused on 
plasma homocysteine as the relevant risk factor, but it is likely that folate and metabolically related B vitamins 
have protective roles against disease that are independent of their homocysteine-lowering effects [178].
6.3 One-carbon metabolism, MTHFR and blood pressure
The frequency of the MTHFR  677 TT genotype is 10% worldwide, however, the distribution varies according 
to geographical area, in that it ranges 0–3% (in Africa), 8–11% (in Australia), 3–18% (in United States), 8–20% 
(in China) and 4–26% (in Europe) [179]. The highest reported frequency of the TT genotype is in Mexico (32%) 
[179]. In addition, geographical gradients in MTHFR  genotype frequencies in Europe (north to south increase) 
and China (south to north increase) have been reported [179,180]. As well as geographical variations, ethnicity 
also appears to influence the frequencies of MTHFR  genotypes; populations of African, European and 
American Hispanic ancestry have a low, intermediate and high TT genotype distribution, respectively [179]. 
Notably, in Mexico, the TT genotype has been shown to be as high as 44% in Mexican Amerindians [181]. 
Collectively, these findings confirm the impact of ethnogeographic variations in the frequency and distribution of 
the MTHFR  677 TT genotype.
At a molecular level, the C677T polymorphism in the MTHFR  gene is known to cause a substitution of the 
amino acid alanine to valine in the protein, producing a thermolabile enzyme with a reduced activity [182]. 
Elevated homocysteine concentrations occur in individuals with the MTHFR  677 TT genotype and is the widely 
recognised phenotype [182]. Hyperhomocysteinaemia has in turn been causatively associated with an increased 
risk of CVD although its role remains somewhat controversial [154]. Molecular evidence shows that the 
increased propensity for the variant form of MTHFR to dissociate from its FAD co-factor is responsible for the 
reduced enzyme activity of the variant enzyme in the TT genotype [183]. Interestingly, human intervention trials 
have reported a marked decrease in homocysteine concentrations in response to riboflavin supplementation, 
specifically in individuals with the TT genotype, suggesting that riboflavin can restore reduced MTHFR enzyme 
activity in vivo [184].
As previously mentioned, evidence from GWAS and clinical studies points to a role for one-carbon metabolism 
in BP and raises the possibility that intervention with relevant B vitamins may have a role in modulating BP. In 
this regard, a highly novel role for riboflavin in BP has emerged over the last decade from studies conducted at 
this Centre. The first of these was a 16-week RCT with riboflavin (1.6 mg/day) in premature CVD patients 
which showed that specifically in those with the MTHFR  677  TT genotype, systolic (−13.4  mmHg) and 
diastolic (−7.5 mmHg) BP was highly responsive to riboflavin [185]. At a 4-year follow-up study, these high-
risk patients with the TT genotype remained hypertensive despite the fact that antihypertensive polytherapy had 
been introduced in the intervening period; BP control was achieved again only in response to riboflavin [186]. In 
a third trial, it was shown that the genotype-specific lowering of BP in response to riboflavin was not confined to 
high-risk CVD patients, but was also demonstrated in hypertensive individuals without overt CVD [187]. In 
summary, these randomised trials show that targeted riboflavin supplementation in genetically at-risk 
hypertensive adults with or without CVD can effectively lower systolic BP by between 6 and 13  mmHg, 
irrespective of antihypertensive medication. The magnitude of such BP reductions could have an important 
clinical impact, given that a reduction in systolic BP of 10 mmHg is estimated to decrease stroke risk by 40% [5]. 
However, the effect of riboflavin supplementation on BP in individuals with the TT genotype has not yet been 
investigated in other populations outside of Northern Ireland or in pregnancy.
In addition to the genotype-specific BP benefits observed in response to riboflavin, evidence for an effect of B 
vitamins on BP in the general population is far weaker (Table 1). In the Vitamin Intervention for Stroke 
Prevention (VISP) trial, 3,649 adults with nondisabling cerebral infarction were randomised to a multivitamin 
containing either a low dose or a high dose of B vitamins (pyridoxine, cobalamin and folic acid) for 2 years, with 
results showing no BP response to B vitamin intervention [188]. Similar findings were also reported by 
McMahon et al. [189], who investigated the effect of combined folic acid, vitamin B6 and B12 on BP in older 
adults and also showed no BP response. In contrast, another 2-year RCT with folic acid (5  mg/day) and 
pyridoxine (250  mg/day) found significant reductions in both systolic (of 3.7  mmHg) and diastolic (of 
1.9 mmHg) BP in response to intervention [190].
6.4 Biological mechanisms linking one-carbon metabolism with blood pressure
The precise mechanisms linking one-carbon metabolism with BP, or explaining the novel role of riboflavin in BP 
in individuals with the TT genotype, are currently unknown. MTHFR enzyme activity is compromised in 
individuals with the homozygous variant MTHFR  677 TT genotype, but appears to be particularly sensitive to 
changes in riboflavin status [184,191]. It could therefore be speculated that in individuals with this genotype, 
there is a higher capacity to replace the inactivated enzyme with optimal riboflavin than with low riboflavin 
status, or that higher riboflavin status prevents the dissociation of the MTHFR co-factor, FAD, from the active 
site or allows its quick replacement, and in turn stabilises the variant MTHFR enzyme [192]. In this way, 
individuals with the TT genotype may have increased riboflavin requirements in order to sustain normal 
MTHFR activity. Restoration of cellular concentrations of 5-MTHF by riboflavin supplementation in those with 
the variant TT genotype may also correct any perturbations in one-carbon metabolism owing to this genetic 
variant, but this remains to be demonstrated [193].
As reviewed elsewhere, the effect of MTHFR on BP is likely to be mediated by nitric oxide, a potent vasodilator 
which regulates endothelial function [192]. It has been shown that patients with the TT genotype have lower 
vascular tissue concentrations of 5-MTHF, which in turn are linked with nitric oxide bioavailability and 
endothelial function [194,195]. Given that riboflavin supplementation appears to restore MTHFR activity in 
these genetically at-risk individuals [184], it could be speculated that 5-MTHF concentrations in the vascular 
tissue would increase in response to riboflavin supplementation, leading to the stimulation of eNOS and an 
increase in nitric oxide bioavailability, thus vasodilation and BP-lowering. Furthermore, apart from reducing 5-
MTHF concentrations, impaired one-carbon metabolism could also compromise the activity of dihydrofolate 
reductase and dihydrobiopterin reductase, impairing the conversion of dihydrobiopterin to tetrahydrobiopterin [
196]. Whereas an increase in the bioavailability of tetrahydrobiopterin stimulates eNOS to produce nitric oxide 
to ultimately induce vasodilation, an accumulation of dihydrobiopterin leads to the generation of superoxide by 
eNOS [197,198]. Of note, given that riboflavin supplementation has been shown to elicit a BP-lowering 
response that is specific to individuals with the variant TT genotype in MTHFR , a direct effect at the 
flavoprotein binding domain of eNOS is unlikely to be the major mechanism explaining the BP-lowering role of 
riboflavin shown in the aforementioned intervention trials, as such an effect would likely impact BP generally 
and not in the observed MTHFR  genotype-specific manner [199]. Furthermore, although some observational 
studies have suggested a role for homocysteine in BP, randomised trials primarily designed to lower 
homocysteine as a means to reduce CVD showed no corresponding BP response [188,189]. Therefore, 
homocysteine is unlikely to be directly involved in explaining the relationship of one-carbon metabolism with 
BP. Further research in this area is clearly required in order to fully explore these and other biological 
mechanisms linking one-carbon metabolism with BP and hypertension.
7 Conclusions and future work
Hypertension is a public health challenge of global proportions. Currently, antihypertensive treatment for the 
achievement of BP control is ineffective for over 40% of individuals suffering from hypertension. This 
emphasises the need for identification of alternative prevention and treatment strategies for hypertension. 
Nutrition is inextricably linked to BP and is involved in the pathogenesis and treatment of hypertension across 
the lifecycle. At this time, the evidence for a protective effect against hypertension is strongest in relation to the 
DASH diet, reduced sodium intake and increased potassium intake. Of interest, emerging evidence implicates 
one-carbon metabolism and related B vitamins in BP. Most notably, supplemental riboflavin may offer an 
effective personalised approach for managing BP in genetically at-risk individuals, albeit all the evidence in this 
area to date comes from trials conducted in Northern Ireland. Hence, further research is warranted to replicate 
such studies in different populations and in cohorts with and without existing hypertension. Mechanistic studies 
which will add to our understanding of the role of this gene-nutrient interaction in BP are also needed. Given 
that BP is known to track from early life, and hypertension in pregnancy is a major risk factor both for adverse 
pregnancy outcomes and later life cardiovascular events, the effect of supplementation with B vitamins on BP in 
pregnant women genetically at-risk of hypertension should be investigated. If a beneficial effect of relevant B 
vitamins on BP during pregnancy is demonstrated, a public health strategy to improve B vitamin status during 
the periconceptional and antenatal period may alleviate the health and economic burden of hypertension in 
pregnancy.
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Highlights
• Hypertension is the leading cause of mortality worldwide, typically from CVD.
• Intervention to effectively lower blood pressure (BP) can reduce CVD risk.
• Nutritional factors can influence BP and risk of hypertension across the lifecycle.
• Emerging evidence points to a novel role for one-carbon metabolism in BP.
• Riboflavin (MTHFR co-factor) lowers BP in individuals with the MTHFR  677 TT genotype.
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